CompletedPhase 2

Role of QRX-3 in Chronic Kidney Disease Patients in Outpatients Clinics

United States127 participantsStarted 2023-03-01

Plain-language summary

QRX-3, a new drug that stabilized the kidney renal tubular cell and increase the activity of NAD ( nicotinamide adenine dineuclotide )within the kidney cells; leading to decrease oxidative changes intracellularly, repair of renal tubular injury and restoration of optimized renal function above baseline , will be studied in patients with progressive chronic kidney disease over 12 months . The result of the change in renal function expressed as creatinine GFR (Glomerular filtration decline) over the treatment duration will be compared in the treatment group will be compared to control group without the medication during that same period .

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patient with Chronic kidney disease stage 3-5 * Estimated Glomerular function by MDRD of less than 60mls/min * Patients with declining renal function ( as measured by eGFR by MDRD ) * Rate of decline of eGFR over the last one year of less than 20% * Negative Serology markers for CKD etiology * Provider perceived adherence to study follow- up Exclusion Criteria: * Rapid rate of decline in kidney function of \> 10 % over 3 months * Symptomatic renal failure * Presence of any suspected Acute renal failure superimposed * Presence of cast , hematuria, or abnormal urinalysis outside of simple UTI * No known reversible cause of renal decline

What they're measuring

daily change in glomerular filtration rate by creatinine in mls/min

Timeframe: 12 months

Trial details

NCT IDNCT06948292

SponsorEbima Clifford Okundaye

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2024-08-30

View on ClinicalTrials.gov More Chronic Kidney Disease Stages 3-5 trials